Health Canada (HC) requires the best quality evidence to support decision-makers and ensure Canada’s regulations are informed by the most up-to-date information available. To achieve this, HC requires access to preserved biological samples from women diagnosed with non malignant gynecological diseases (NMGD). HC analysis of these samples will generate data and results to identify potential associations with specific chemical exposures, which will contribute to supporting scientific evidence for Health Canada’s regulatory efforts to protect Canadians from environmental contaminants.
Get a plain-English breakdown of this tender — what they need, who can bid, how to approach it, and tips for small suppliers. Takes a couple of seconds.